SecBot SecBot

LIMNW

Liminatus Pharma, Inc.
Nasdaq· Biological Products, (No Diagnostic Substances)· Inc. DE· CIK 0001971387 Biotech & Drug Discovery
Warrants of Liminatus Pharma, Inc. · LIMN stock page →
—
Market cap
$53.7K
Nano cap
1 year
−95.1%
from $64.00 · Oct 27
30 days
−26.0%
from $4.27
52-week range
$2.94–102.50
−97% from high · low Oct 23
Avg volume 20D
26.6K
Oct 21 spike 118.8K
Short interest
🔒 Subscribers only
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
2
analyzed by SecBot
SecBot read MIXED 2 reports · latest
Balance 0 bearish · 0 bullish · 2 mixed oldest → newest, height = score
Avg score ·High conf. 1/2
Strongest MIXED Liminatus Pharma entered into a warrant inducement agreement whereby an accredited investor exercised…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InstitutionsMIXED

    Q2 2026: 0 added (0 new), 1 trimmed or exited.

  • TrendDOWNTREND

    19% below its 50-day average. New closing low $2.94 on Oct 23.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
WOLVERINE ASSET MANAGEMENT LLCTRIM13,976$1.0K
WOLVERINE ASSET MANAGEMENT LLCTRIM39,373$1.6K
Clear Street Group Inc.NEAR_EXIT100$4.00
UBS Group AGDOUBLED4,212$147.00
BANK OF AMERICA CORP /DE/TRIM100$4.00
WOLVERINE ASSET MANAGEMENT LLCTRIM62,863$9.3K
UBS Group AGNEAR_EXIT290$43.00
BANK OF AMERICA CORP /DE/TRIM200$29.00

Quarterly 13F filings are due 45 days after each quarter ends.

Earnings setup

Estimates
PeriodEPS est.Range30D rev.Revenue
Current Q———$0.00
Next Q———$0.00
Current FY———$0.00
Next FY———$0.00
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Aug 21, 2026
Trading halt
Halt Resumed: LIMNW — trading resumed after T3 (News and Resumption Times)
Halted 2026-08-20T23:50:00.000Z | Resumed 2026-08-21T13:05:00.000Z
Aug 20, 2026
Trading halt
Trading Halt: LIMNW — T1 (News Pending)
Liminatus Pharma, Inc. | Market: NASDAQ | Code: T1 — News Pending
Aug 20, 2026
Trading halt
Trading Halt: LIMNW — T3 (News and Resumption Times)
Liminatus Pharma, Inc. | Market: NASDAQ | Code: T3 — News and Resumption Times

Short side

FINRA· Oct 15, 2026
🔒 Subscribers only
shares short
Trading halts
Aug 20, 2026Resumption ScheduledResumed
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Aug 21, 2026 Trading halt
Halt Resumed: LIMNW — trading resumed after T3 (News and Resumption Times)
Halted 2026-08-20T23:50:00.000Z | Resumed 2026-08-21T13:05:00.000Z
Jun 30, 2026 Inst.
WOLVERINE ASSET MANAGEMENT LLC — TRIM
13,976 shares ($1.0K)
Jun 3, 2026 SEC
Liminatus Pharma entered into a warrant inducement agreement whereby an accredited investor exercised approximately…
8-K — Impact 5/10
May 20, 2026 SEC
Liminatus Pharma entered a merger agreement to acquire InnocsAI LLC, a private CAR-T therapy company, for 1.6 billion…
8-K — Impact 6/10
Mar 31, 2026 Inst.
WOLVERINE ASSET MANAGEMENT LLC — TRIM
39,373 shares ($1.6K)

SecBot reports

2 filings · 0 bullish · 0 bearish · 2 mixed
All LIMNW filing & press-release reports (2)